Cargando…

The Diverse Analysis Identifies Mutated KRAS Associated With Radioresistance in Non-Small Cell Lung Cancer

BACKGROUND: To analyze the relationship between V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) status and radioresistance in non-small cell lung cancer (NSCLC), we identified potential genotypic differences and pathways involved. METHODS: We retrospectively analyzed epidermal growth fac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Dao Qi, Liu, Ying, Yu, Zhi Jian, Zhang, Ru Hua, Li, Ai Wu, Gong, Feng Ying, Wang, Wei, Xiao, Wei, Fan, Qin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076151/ https://www.ncbi.nlm.nih.gov/pubmed/35571341 http://dx.doi.org/10.14740/wjon1465

Ejemplares similares

Review: Mechanisms and perspective treatment of radioresistance in non-small cell lung cancer
por: Zhou, Ting, et al.
Publicado: (2023)

Effect of Shengmai Yin on Epithelial-Mesenchymal Transition of Nasopharyngeal Carcinoma Radioresistant Cells
por: Wang, Ze-tai, et al.
Publicado: (2022)

A Real-World Study in Advanced Non–Small Cell Lung Cancer with KRAS Mutations
por: Lei, Lei, et al.
Publicado: (2019)

NRF2-pathway mutations predict radioresistance in non-small cell lung cancer
por: Kinslow, Connor J., et al.
Publicado: (2022)

Realities of KRAS-mutated non-small cell lung cancer
por: Min, Young Joo
Publicado: (2017)

Clinicopathologic characteristics and survival outcome in patients with advanced lung adenocarcinoma and KRAS mutation
por: Yang, Shifeng, et al.
Publicado: (2018)

Characterization of KRAS Mutation Subtypes in Non–small Cell Lung Cancer
por: Judd, Julia, et al.
Publicado: (2021)

Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer
por: O’Sullivan, Éabha, et al.
Publicado: (2023)

Insights into EGFR Mutations and Oncogenic KRAS Mutations in Non-Small-Cell Lung Cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

Radioresistance of Non-Small Cell Lung Cancers and Therapeutic Perspectives
por: Césaire, Mathieu, et al.
Publicado: (2022)

Concurrent ROS1 gene rearrangement and KRAS mutation in lung adenocarcinoma: A case report and literature review
por: Zhu, You‐cai, et al.
Publicado: (2017)

Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells
por: Xie, Chun, et al.
Publicado: (2017)

Biochip-Based Detection of KRAS Mutation in Non-Small Cell Lung Cancer
por: Kriegshäuser, Gernot, et al.
Publicado: (2011)

Intratumor heterogeneity and tissue distribution of KRAS mutation in non-small cell lung cancer: implications for detection of mutated KRAS oncogene in exhaled breath condensate
por: Kordiak, Jacek, et al.
Publicado: (2018)

Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition
por: Vaclova, Tereza, et al.
Publicado: (2022)

Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation
por: Zeng, Da-xiong, et al.
Publicado: (2017)

Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells
por: Brunelli, Laura, et al.
Publicado: (2014)

Dual drive coexistence of ALK rearrangement and KRAS mutation advanced lung adenocarcinoma and response to crizotinib
por: Zhu, You-Cai, et al.
Publicado: (2019)

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2020)

Caveolin-1 promotes radioresistance via IRGM-regulated autophagy in lung cancer
por: Chen, Xi, et al.
Publicado: (2021)

Stromal cell‐derived small extracellular vesicles enhance radioresistance of prostate cancer cells via interleukin‐8‐induced autophagy
por: Wang, Xiumei, et al.
Publicado: (2023)

Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients
por: Liu, Si-Yang, et al.
Publicado: (2020)

Oncogenic KRAS drives radioresistance through upregulation of NRF2-53BP1-mediated non-homologous end-joining repair
por: Yang, Linlin, et al.
Publicado: (2021)

Increased activity of CHK enhances the radioresistance of MCF-7 breast cancer stem cells
por: YANG, ZHI-XUE, et al.
Publicado: (2015)

Inhibition of livin overcomes radioresistance in nasopharyngeal carcinoma cells
por: Ma, Fei, et al.
Publicado: (2020)

Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer
por: Sun, Jong-Mu, et al.
Publicado: (2013)

Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance
por: Reita, Damien, et al.
Publicado: (2022)

KRAS Mutations Impact Clinical Outcome in Metastatic Non-Small Cell Lung Cancer
por: Eklund, Ella A., et al.
Publicado: (2022)

Neighborhood disadvantage is associated with KRAS-mutated non-small cell lung cancer risk
por: Wing, Sam E., et al.
Publicado: (2022)

EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients
por: Lu, Hong-Yang, et al.
Publicado: (2018)

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2021)

Bmi-1 induces radioresistance in MCF-7 mammary carcinoma cells
por: LIU, ZHI-GANG, et al.
Publicado: (2011)

Mutation Analysis of Radioresistant Early-Stage Cervical Cancer
por: Oike, Tae, et al.
Publicado: (2021)

The Prevalence and Concurrent Pathogenic Mutations of KRAS(G12C) in Northeast Chinese Non-small-cell Lung Cancer Patients
por: Liu, Yan, et al.
Publicado: (2021)

PIK3CA Mutations Frequently Coexist with EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup
por: Wang, Lei, et al.
Publicado: (2014)

Molecular Characteristics and the Effect of KRAS Mutation on the Prognosis of Immunotherapy in Non-Small Cell Lung Cancer in Xinjiang, China
por: Gu, Guomin, et al.
Publicado: (2022)

Identifying relationships between imaging phenotypes and lung cancer-related mutation status: EGFR and KRAS
por: Pinheiro, Gil, et al.
Publicado: (2020)

KRAS and EGFR mutations coexisting in lung adenocarcinoma
por: Sousa, Vitor, et al.
Publicado: (2010)

EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
por: Jang, Tae Won, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_mvae45ltlku4hp7i10644sm1kh